Progesterone vaginal capsule versus vaginal gel for luteal support in normoresponder women undergoing long agonist IVF/ICSI cycles.
The aim of the study was to investigate the effects of two different vaginal progesterone forms, administered for luteal phase support, on pregnancy outcomes in normoresponder women aged < 35, who underwent long agonist IVF/ICSI-ET cycles.



A retrospective cohort analysis was designed. Normoresponders with primary infertility, who un-derwent IVF/ICSI-ET cycles employing GnRH analogue and who received progesterone as either capsule or gel form for LPS following a single embryo transfer, were analyzed. The cycles were categorized into two groups: micronized progesterone vaginal capsule 600 mg/day (Group 1, n = 78) and progesterone vaginal gel 180 mg/day (Group 2, n = 99). Positive β-hCG, clinical pregnancy and ongoing pregnancy rates were analyzed.



Both, demographic and stimulation characteristics were comparable between the groups. No difference was observed between the capsule and the gel groups regarding positive β-hCG (33.3% and 28.3%, respectively; p = 0.580), clinical pregnancy (26.9% and 22.2%, respectively; p = 0.584), and ongoing pregnancy rates (21.8% and 20.2%, respectively; p = 0.942) after treatment completion.



In long agonist IVF/ICSI-ET cycles, positive β-hCG, clinical pregnancy and ongoing pregnancy rates do not significantly differ between normoresponder patients receiving micronized progesterone vaginal capsule and those receiv-ing progesterone vaginal gel for LPS.
İsmet
İ
Gün
ozkan_ozdamar35@hotmail.com.
Özkan
Ö
Özdamar
Sadık
S
Şahin
Elçin
E
Çetingöz
Kenan
K
Sofuoğlu
D000328:Adult; D002214:Capsules; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D006801:Humans; D008183:Luteal Phase / Q000187:drug effects* / Q000502:physiology; D011247:Pregnancy; D011256:Pregnancy Outcome; D018873:Pregnancy Rate; D011374:Progesterone / Q000008:administration & dosage / Q000009:adverse effects; D011372:Progestins / Q000008:administration & dosage / Q000009:adverse effects; D012189:Retrospective Studies; D014622:Vaginal Creams, Foams, and Jellies
D002214:Capsules; D011372:Progestins; D014622:Vaginal Creams, Foams, and Jellies; D011374:Progesterone
in vitro fertilization; long agonist protocol; progesterone; vaginal capsule; vaginal gel